Table 3.

Treatment characteristics for renal cancer patients treated for metastatic disease with sunitinib or sorafenib in the first- or second-line setting

Treatment	Total n = 136
Sunitinib, n (%)	77 (57)
Sorafenib, n (%)	59 (43)
Side effects leading to discontinuation of treatment, n (%)	30 (22)
Sunitinib	16
Sorafenib	14
Treated until progression/end of follow-up, n (%)	106 (78)
Sunitinib	61
Sorafenib	45
Median PFS, months (range)	7 (0.5–40)
Sunitinib	8
Sorafenib	6
Still under treatment, n (%)	12 (11)